Hypoxia-induced remodelling of PDE4 isoform expression and cAMP handling in human pulmonary artery smooth muscle cells

European Journal of Cell Biology

Volumn 85, Issue 7, 2006, Pages 679-691

  Millen, Jennifer ^a   MacLean, Margaret R ^a   Houslay, Miles D ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Human pulmonary smooth muscle cells; Hypoxia; PDE4 isoforms; Regulation; Signalling

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADENYLATE CYCLASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIN 1; FORSKOLIN; INDOMETACIN; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE; MITOGENIC AGENT; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; SEROTONIN; UO 126;

ARTERY MUSCLE; ARTICLE; ATTENUATION; CELL COMPARTMENTALIZATION; CELL HYPOXIA; CELL PROTECTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; PULMONARY ARTERY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION;

EID: 33744975520     PISSN: 01719335     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcb.2006.01.006     Document Type: Article

References (84)

1. Baillie G.S., and Houslay M.D. Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr. Opin. Cell Biol. 17 (2005) 129-134
2. Baillie G.S., MacKenzie S.J., McPhee I., and Houslay M.D. Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br. J. Pharmacol. 131 (2000) 811-819
3. Baillie G.S., MacKenzie S.J., and Houslay M.D. Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK). Mol. Pharmacol. 60 (2001) 1100-1111
4. Baillie G.S., Scott J.D., and Houslay M.D. Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett. 579 (2005) 3264-3270
5. Barber R., Baillie G.S., Bergmann R., Shepherd M.C., Sepper R., Houslay M.D., and Heeke G.V. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am. J. Physiol. Lung Cell Mol. Physiol. 287 (2004) L332-L343
6. Beavo J.A., and Brunton L.L. Cyclic nucleotide research - still expanding after half a century. Nat. Rev. Mol. Cell Biol. 3 (2002) 710-718
7. Blaschke F., Stawowy P., Goetze S., Hintz O., Grafe M., Kintscher U., Fleck E., and Graf K. Hypoxia activates beta(1)-integrin via ERK 1/2 and p38 MAP kinase in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 296 (2002) 890-896
8. Bolger G.B., Erdogan S., Jones R.E., Loughney K., Scotland G., Hoffmann R., Wilkinson I., Farrell C., and Houslay M.D. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem. J. 328 (1997) 539-548
9. Bradbury D.A., Newton R., Zhu Y.M., Stocks J., Corbett L., Holland E.D., Pang L.H., and Knox A.J. Effect of bradykinin, TGF-beta1, IL-1beta, and hypoxia on COX-2 expression in pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 283 (2002) L717-L725
10. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
11. Christman B.W., McPherson C.D., Newman J.H., King G.A., Bernard G.R., Groves B.M., and Loyd J.E. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327 (1992) 70-75
12. Clapp L.H., Finney P., Turcato S., Tran S., Rubin L.J., and Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am. J. Respir. Cell Mol. Biol. 26 (2002) 194-201
13. Conti M., and Jin S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63 (1999) 1-38
14. Conti M., Richter W., Mehats C., Livera G., Park J.Y., and Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J. Biol. Chem. 278 (2003) 5493-5496
15. Cooper D.M. Regulation and organization of adenylyl cyclases and cAMP. Biochem. J. 375 (2003) 517-529
16. Debey S., Meyer-Kirchrath J., and Schror K. Regulation of cyclooxygenase-2 expression by iloprost in human vascular smooth muscle cells. Role of transcription factors CREB and ICER. Biochem. Pharmacol. 65 (2003) 979-988
17. Deng Z., Morse J.H., Slager S.L., Cuervo N., Moore K.J., Venetos G., Kalachikov S., Cayanis E., Fischer S.G., Barst R.J., Hodge S.E., and Knowles J.A. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet. 67 (2000) 737-744
18. Eddahibi S., Humbert M., Fadel E., Raffestin B., Darmon M., Capron F., Simonneau G., Dartevelle P., Hamon M., and Adnot S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest. 108 (2001) 1141-1150
19. El-Haroun H., Bradbury D., Clayton A., and Knox A.J. Interleukin-1beta, transforming growth factor-beta1, and bradykinin attenuate cyclic AMP production by human pulmonary artery smooth muscle cells in response to prostacyclin analogues and prostaglandin E2 by cyclooxygenase-2 induction and downregulation of adenylyl cyclase isoforms 1, 2, and 4. Circ. Res. 94 (2004) 353-361
20. Engels P., Sullivan M., Muller T., and Lubbert H. Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C). FEBS Lett. 358 (1995) 305-310
21. Francis S.H., Turko I.V., and Corbin J.D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65 (2001) 1-52
22. Giaid A. Nitric oxide and endothelin-1 in pulmonary hypertension. Chest 114 (1998) 208S-212S
23. Graves L.M., Bornfeldt K.E., Sidhu J.S., Argast G.M., Raines E.W., Ross R., Leslie C.C., and Krebs E.G. Platelet-derived growth factor stimulates protein kinase A through a mitogen-activated protein kinase-dependent pathway in human arterial smooth muscle cells. J. Biol. Chem. 271 (1996) 505-511
24. Hanze J., Eul B.G., Savai R., Krick S., Goyal P., Grimminger F., Seeger W., and Rose F. RNA interference for HIF-1alpha inhibits its downstream signalling and affects cellular proliferation. Biochem. Biophys. Res. Commun. 312 (2003) 571-577
25. Hill E.V., Houslay M.D., and Baillie G.S. Investigation of extracellular signal-regulated kinase 2 mitogen-activated protein kinase phosphorylation and regulation of activity of PDE4 cyclic adenosine monophosphate-specific phosphodiesterases. Methods Mol. Biol. 307 (2005) 225-237
26. Hoffmann R., Baillie G.S., MacKenzie S.J., Yarwood S.J., and Houslay M.D. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J. 18 (1999) 893-903
27. Houslay M.D. The long and short of vascular smooth muscle phosphodiesterase-4 as a putative therapeutic target. Mol. Pharmacol. 68 (2005) 563-567
28. Houslay M.D., and Adams D.R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. 370 (2003) 1-18
29. Houslay M.D., and Kolch W. Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. Mol. Pharmacol. 58 (2000) 659-668
30. Houslay M.D., Sullivan M., and Bolger G.B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol. 44 (1998) 225-342
31. Houslay M.D., Schafer P., and Zhang K.Y. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov. Today 10 (2005) 1503-1519
32. Huang Z., Ducharme Y., Macdonald D., and Robichaud A. The next generation of PDE4 inhibitors. Curr. Opin. Chem. Biol. 5 (2001) 432-438
33. Huston E., Lumb S., Russell A., Catterall C., Ross A.H., Steele M.R., Bolger G.B., Perry M.J., Owens R.J., and Houslay M.D. Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3. Biochem. J. 328 (1997) 549-558
34. Jeffery P. Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD. Pulm. Pharmacol. Ther. 18 (2005) 9-17
35. Jeffery T.K., and Wanstall J.C. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol. Ther. 92 (2001) 1-20
36. Lane K.B., Machado R.D., Pauciulo M.W., Thomson J.R., Phillips III J.A., Loyd J.E., Nichols W.C., and Trembath R.C. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat. Genet. 26 (2000) 81-84
37. Le Jeune I.R., Shepherd M., Van Heeke G., Houslay M.D., and Hall I.P. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter. J. Biol. Chem. 277 (2002) 35980-35989
38. Lefkowitz R.J., and Shenoy S.K. Transduction of receptor signals by beta-arrestins. Science 308 (2005) 512-517
39. Lin L.L., Wartmann M., Lin A.Y., Knopf J.L., Seth A., and Davis R.J. cPLA2 is phosphorylated and activated by MAP kinase. Cell 72 (1993) 269-278
40. Lynch M.J., Baillie G.S., Mohamed A., Li X., Maisonneuve C., Klussmann E., van Heeke G., and Houslay M.D. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J. Biol. Chem. 280 (2005) 33178-33189
41. Machado R.D., Pauciulo M.W., Thomson J.R., Lane K.B., Morgan N.V., Wheeler L., Phillips III J.A., Newman J., Williams D., Galie N., Manes A., McNeil K., Yacoub M., Mikhail G., Rogers P., Corris P., Humbert M., Donnai D., Martensson G., Tranebjaerg L., Loyd J.E., Trembath R.C., and Nichols W.C. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Genet. 68 (2001) 92-102
42. MacKenzie S.J., and Houslay M.D. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem. J. 347 (2000) 571-578
43. MacKenzie S.J., Yarwood S.J., Peden A.H., Bolger G.B., Vernon R.G., and Houslay M.D. Stimulation of p70S6 kinase via a growth hormone-controlled phosphatidylinositol 3-kinase pathway leads to the activation of a PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadipocytes. Proc. Natl. Acad. Sci. USA 95 (1998) 3549-3554
44. MacKenzie S.J., Baillie G.S., McPhee I., Bolger G.B., and Houslay M.D. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions. J. Biol. Chem. 275 (2000) 16609-16617
45. MacKenzie S.J., Baillie G.S., McPhee I., MacKenzie C., Seamons R., McSorley T., Millen J., Beard M.B., van Heeke G., and Houslay M.D. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in upstream conserved region 1 (UCR1). Br. J. Pharmacol. 136 (2002) 421-433
46. MacLean M.R. Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension?. J. Lab. Clin. Med. 134 (1999) 105-114
47. MacLean M.R., Sweeney G., Baird M., McCulloch K.M., Houslay M., and Morecroft I. 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br. J. Pharmacol. 119 (1996) 917-930
48. Maclean M.R., Johnston E.D., McCulloch K.M., Pooley L., Houslay M.D., and Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J. Pharmacol. Exp. Ther. 283 (1997) 619-624
49. Manganiello V.C., and Degerman E. Cyclic nucleotide phosphodiesterases (PDEs): diverse regulators of cyclic nucleotide signals and inviting molecular targets for novel therapeutic agents. Thromb. Haemost. 82 (1999) 407-411
50. Marchese A., Chen C., Kim Y.M., and Benovic J.L. The ins and outs of G protein-coupled receptor trafficking. Trends Biochem. Sci. 28 (2003) 369-376
51. Marchmont R.J., and Houslay M.D. A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. Biochem. J. 187 (1980) 381-392
52. McPhee I., Yarwood S.J., Scotland G., Huston E., Beard M.B., Ross A.H., Houslay E.S., and Houslay M.D. Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition. J. Biol. Chem. 274 (1999) 11796-11810
53. Mehats C., Tanguy G., Dallot E., Robert B., Rebourcet R., Ferre F., and Leroy M.J. Selective up-regulation of phosphodiesterase-4 cyclic adenosine 3′,5′-monophosphate (cAMP)-specific phosphodiesterase variants by elevated cAMP content in human myometrial cells in culture. Endocrinology 140 (1999) 3228-3237
54. Millar J.K., Pickard B.S., Mackie S., James R., Christie S., Buchanan S.R., Malloy M.P., Chubb J.E., Huston E., Baillie G.S., Thomson P.A., Hill E.V., Brandon N.J., Rain J.C., Camargo L.M., Whiting P.J., Houslay M.D., Blackwood D.H., Muir W.J., and Porteous D.J. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310 (2005) 1187-1191
55. Mongillo M., McSorley T., Evellin S., Sood A., Lissandron V., Terrin A., Huston E., Hannawacker A., Lohse M.J., Pozzan T., Houslay M.D., and Zaccolo M. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ. Res. 95 (2004) 67-75
56. Mooradian D.L., Fernandes B., Diglio C.A., and Lester B.R. Angiopeptin (BIM23014C) inhibits vascular smooth muscle cell migration in vitro through a G-protein-mediated pathway and is associated with inhibition of adenylyl cyclase and cyclic AMP accumulation. J. Cardiovasc. Pharmacol. 25 (1995) 611-618
57. Naeije R., and Rondelet B. Pathobiology of pulmonary arterial hypertension. Bull. Mem. Acad. R. Med. Belg. 159 (2004) 219-226
58. O'Donnell J.M., and Zhang H.T. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol. Sci. 25 (2004) 158-163
59. Obernolte R., Ratzliff J., Baecker P.A., Daniels D.V., Zuppan P., Jarnagin K., and Shelton E.R. Multiple splice variants of phosphodiesterase PDE4C cloned from human lung and testis. Biochim. Biophys. Acta 1353 (1997) 287-297
60. Oger S., Mehats C., Dallot E., Ferre F., and Leroy M.J. Interleukin-1beta induces phosphodiesterase 4B2 expression in human myometrial cells through a prostaglandin E2- and cyclic adenosine 3′,5′-monophosphate-dependent pathway. J. Clin. Endocrinol. Metab. 87 (2002) 5524-5531
61. Owens R.J., Lumb S., Rees-Milton K., Russell A., Baldock D., Lang V., Crabbe T., Ballesteros M., and Perry M.J. Molecular cloning and expression of a human phosphodiesterase 4C. Cell Signal. 9 (1997) 575-585
62. Palmer D., Tsoi K., and Maurice D.H. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. Circ. Res. 82 (1998) 852-861
63. Pan X., Arauz E., Krzanowski J.J., Fitzpatrick D.F., and Polson J.B. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem. Pharmacol. 48 (1994) 827-835
64. Phillips P.G., Long L., Wilkins M.R., and Morrell N.W. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am. J. Physiol. Lung Cell Mol. Physiol. 288 (2005) L103-L115
65. Pyne N.J., Tolan D., and Pyne S. Bradykinin stimulates cAMP synthesis via mitogen-activated protein kinase-dependent regulation of cytosolic phospholipase A2 and prostaglandin E2 release in airway smooth muscle. Biochem. J. 328 (1997) 689-694
66. Rena G., Begg F., Ross A., MacKenzie C., McPhee I., Campbell L., Huston E., Sullivan M., and Houslay M.D. Molecular cloning, genomic positioning, promoter identification, and characterization of the novel cyclic AMP-specific phosphodiesterase PDE4A10. Mol. Pharmacol. 59 (2001) 996-1011
67. Schermuly R.T., Kreisselmeier K.P., Ghofrani H.A., Samidurai A., Pullamsetti S., Weissmann N., Schudt C., Ermert L., Seeger W., and Grimminger F. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ. Res. 94 (2004) 1101-1108
68. Sette C., and Conti M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J. Biol. Chem. 271 (1996) 16526-16534
69. Sheares K.K., Jeffery T.K., Long L., Yang X., and Morrell N.W. Differential effects of TGF-beta1 and BMP-4 on the hypoxic induction of cyclooxygenase-2 in human pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 287 (2004) L919-L927
70. Shepherd M.C., Baillie G.S., Stirling D.I., and Houslay M.D. Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. Br. J. Pharmacol. 142 (2004) 339-351
71. Spence S., Rena G., Sweeney G., and Houslay M.D. Induction of Ca2+/calmodulin-stimulated cyclic AMP phosphodiesterase (PDE1) activity in Chinese hamster ovary cells (CHO) by phorbol 12-myristate 13-acetate and by the selective overexpression of protein kinase C isoforms. Biochem. J. 310 (1995) 975-982
72. Strange J.W., Wharton J., Phillips P.G., and Wilkins M.R. Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clin. Sci. London 102 (2002) 253-268
73. Sullivan M., Olsen A.S., and Houslay M.D. Genomic organisation of the human cyclic AMP-specific phosphodiesterase PDE4C gene and its chromosomal localisation to 19p13.1, between RAB3A and JUND. Cell Signal. 11 (1999) 735-742
74. Suzuki Y.J., Day R.M., Tan C.C., Sandven T.H., Liang Q., Molkentin J.D., and Fanburg B.L. Activation of GATA-4 by serotonin in pulmonary artery smooth muscle cells. J. Biol. Chem. 278 (2003) 17525-17531
75. Tasken K., and Aandahl E.M. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol. Rev. 84 (2004) 137-167
76. Thompson W.J., Brooker G., and Appleman M.M. Assay of cyclic nucleotide phosphodiesterases with radioactive substrates. Methods Enzymol. 38 (1974) 205-212
77. Thomson J., Machado R., Pauciulo M., Morgan N., Yacoub M., Corris P., McNeil K., Loyd J., Nichols W., and Trembath R. Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein type II receptor. J. Heart Lung Transplant. 20 (2001) 149
78. Thorin-Trescases N., Orlov S.N., Taurin S., Dulin N.O., Allen B.G., deBlois D., Tremblay J., Pshezhetsky A.V., and Hamet P. Antiproliferative effect of brief exposure to cholera toxin in vascular smooth muscle cells: role of cAMP and protein kinase A. Can. J. Physiol. Pharmacol. 79 (2001) 471-480
79. Tilley D.G., and Maurice D.H. Vascular smooth muscle cell phenotype-dependent phosphodiesterase 4D short form expression: role of differential histone acetylation on cAMP-regulated function. Mol. Pharmacol. 68 (2005) 596-605
80. Wallace D.A., Johnston L.A., Huston E., MacMaster D., Houslay T.M., Cheung Y.F., Campbell L., Millen J.E., Smith R.A., Gall I., Knowles R.G., Sullivan M., and Houslay M.D. Identification and characterization of PDE4A11, a novel, widely expressed long isoform encoded by the human PDE4A cAMP phosphodiesterase gene. Mol. Pharmacol. 67 (2005) 1920-1934
81. Wharton J., Davie N., Upton P.D., Yacoub M.H., Polak J.M., and Morrell N.W. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 102 (2000) 3130-3136
82. Wong S.T., Baker L.P., Trinh K., Hetman M., Suzuki L.A., Storm D.R., and Bornfeldt K.E. Adenylyl cyclase 3 mediates prostaglandin E(2)-induced growth inhibition in arterial smooth muscle cells. J. Biol. Chem. 276 (2001) 34206-34212
83. Wong W., and Scott J.D. AKAP signalling complexes: focal points in space and time. Nat. Rev. Mol. Cell Biol. 5 (2004) 959-970
84. Yang X., Sheares K.K., Davie N., Upton P.D., Taylor G.W., Horsley J., Wharton J., and Morrell N.W. Hypoxic induction of cox-2 regulates proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 27 (2002) 688-696